MX2020004319A - Variantes de beta-lactamasas. - Google Patents
Variantes de beta-lactamasas.Info
- Publication number
- MX2020004319A MX2020004319A MX2020004319A MX2020004319A MX2020004319A MX 2020004319 A MX2020004319 A MX 2020004319A MX 2020004319 A MX2020004319 A MX 2020004319A MX 2020004319 A MX2020004319 A MX 2020004319A MX 2020004319 A MX2020004319 A MX 2020004319A
- Authority
- MX
- Mexico
- Prior art keywords
- improved
- beta
- activity
- isolated polypeptide
- stability
- Prior art date
Links
- 108090000204 Dipeptidase 1 Proteins 0.000 title 1
- 102000006635 beta-lactamase Human genes 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 150000003952 β-lactams Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
- C12Y305/02006—Beta-lactamase (3.5.2.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un polipéptido aislado que tiene actividad betalactámica y secuencias de ácido nucleico que codifican el polipéptido. El polipéptido aislado de la invención es una variante de VIM-2 con propiedades mejoradas tales como estabilidad de proteasa mejorada, estabilidad en medio intestinal, actividad mejorada contra uno o más antibióticos, actividad específica mejorada y/o producción mejorada en una célula hospedante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17198414 | 2017-10-25 | ||
PCT/EP2018/079223 WO2019081614A1 (en) | 2017-10-25 | 2018-10-24 | VARIANTS OF BETA-LACTAMASE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020004319A true MX2020004319A (es) | 2020-10-12 |
Family
ID=60331400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004319A MX2020004319A (es) | 2017-10-25 | 2018-10-24 | Variantes de beta-lactamasas. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11365403B2 (es) |
EP (1) | EP3701022B1 (es) |
JP (1) | JP7223015B2 (es) |
KR (1) | KR20200074982A (es) |
CN (1) | CN111247246A (es) |
BR (1) | BR112020007974A2 (es) |
CA (1) | CA3077603A1 (es) |
IL (1) | IL273728A (es) |
MX (1) | MX2020004319A (es) |
WO (1) | WO2019081614A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11365403B2 (en) * | 2017-10-25 | 2022-06-21 | Da Volterra | Beta-lactamase variants |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI920206A0 (fi) | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
DE4422198C2 (de) | 1994-06-24 | 1997-08-28 | Audi Ag | Verfahren zum Steuern der elektrischen Beheizung eines Katalysators |
NZ330940A (en) | 1997-07-24 | 2000-02-28 | F | Production of consensus phytases from fungal origin using computer programmes |
FR2843302B1 (fr) | 2002-08-09 | 2004-10-22 | Centre Nat Rech Scient | Forme galenique pour la delivrance colique de principes actifs |
EP2407433A1 (en) | 2010-07-15 | 2012-01-18 | Da Volterra | Methods for the inactivation of antibiotics |
CN102757950A (zh) * | 2011-04-25 | 2012-10-31 | 天津市国际生物医药联合研究院 | 超级细菌新德里金属依赖型β-内酰胺酶NDM-1的表达纯化及β-内酰胺酶NDM-1的晶体结构 |
CN107148473B (zh) * | 2014-10-08 | 2021-08-06 | 合成生物制品有限公司 | β-内酰胺酶制剂及其用途 |
EP3420078B1 (en) * | 2016-02-23 | 2022-05-25 | Da Volterra | Beta-lactamase variants |
US10988749B2 (en) * | 2016-02-23 | 2021-04-27 | Da Volterra | Beta-lactamase variants |
US11365403B2 (en) * | 2017-10-25 | 2022-06-21 | Da Volterra | Beta-lactamase variants |
-
2018
- 2018-10-24 US US16/757,968 patent/US11365403B2/en active Active
- 2018-10-24 WO PCT/EP2018/079223 patent/WO2019081614A1/en active Application Filing
- 2018-10-24 EP EP18789169.2A patent/EP3701022B1/en active Active
- 2018-10-24 CA CA3077603A patent/CA3077603A1/en active Pending
- 2018-10-24 MX MX2020004319A patent/MX2020004319A/es unknown
- 2018-10-24 CN CN201880068725.0A patent/CN111247246A/zh active Pending
- 2018-10-24 BR BR112020007974-0A patent/BR112020007974A2/pt unknown
- 2018-10-24 JP JP2020543711A patent/JP7223015B2/ja active Active
- 2018-10-24 KR KR1020207014812A patent/KR20200074982A/ko not_active Application Discontinuation
-
2020
- 2020-03-31 IL IL273728A patent/IL273728A/en unknown
-
2022
- 2022-05-16 US US17/745,205 patent/US20220356459A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20200074982A (ko) | 2020-06-25 |
EP3701022B1 (en) | 2023-03-01 |
US20220356459A1 (en) | 2022-11-10 |
JP2021501603A (ja) | 2021-01-21 |
BR112020007974A2 (pt) | 2020-10-27 |
JP7223015B2 (ja) | 2023-02-15 |
CA3077603A1 (en) | 2019-05-02 |
US11365403B2 (en) | 2022-06-21 |
US20200318094A1 (en) | 2020-10-08 |
WO2019081614A1 (en) | 2019-05-02 |
EP3701022A1 (en) | 2020-09-02 |
IL273728A (en) | 2020-05-31 |
CN111247246A (zh) | 2020-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4219704A3 (en) | Aprl-clade protease variants and uses thereof | |
MX2023010757A (es) | Variantes de proteasa y sus usos. | |
MY197415A (en) | Functional expression of monooxygenase and methods of use | |
BR112016003256A2 (pt) | micro-organismos modificados para usar fontes não convencionais de fósforo ou enxofre | |
BR112018011073A2 (pt) | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização | |
BR112018073628A2 (pt) | anticorpos antimiostatina e métodos de utilização | |
EP4234693A3 (en) | Bacillus gibsonii-clade serine proteases | |
MX2023001119A (es) | Variantes de enzimas y polinucleotidos que las codifican. | |
BR112016002038A2 (pt) | Variantes de enzimas | |
MX2015004088A (es) | Proteasas modificadas con inteina, su produccion y aplicaciones industriales. | |
AR096270A1 (es) | Composiciones detergentes | |
MX2014013329A (es) | Variantes de enzimas mejoradas. | |
WO2016022377A3 (en) | Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen | |
MX2016003737A (es) | Microorganismo recombinante para la mejora de produccion de productos quimicos finos. | |
MY193287A (en) | Recombinant microorganism for improved production of fine chemicals | |
MX2016011745A (es) | Variantes de hppd y metodos de uso. | |
AR100606A1 (es) | Variantes de lipasas y polinucleótidos que las codifican | |
IN2014DN10710A (es) | ||
MX2018011980A (es) | 3-epimerasa y polinucleotido que la codifica. | |
AR101147A1 (es) | Composiciones y métodos que comprenden una variante de xilanasa | |
BR112015021960A2 (pt) | Células hospedeiras e métodos de uso | |
EA201791118A1 (ru) | Кодон-оптимизированный полинуклеотид для экспрессии crmна высоком уровне | |
AR102950A1 (es) | Variantes de lipasa y polinucleótidos que las codifican | |
CL2018000164A1 (es) | Vector recombinante del virus orf. | |
BR112018074437A2 (pt) | cepa de bacillus licheniformis com atividade probiótica |